|
gptkbp:instance_of
|
gptkb:chemical_compound
|
|
gptkbp:administered_by
|
oral route
clinical settings
patients with cancer
drug B
|
|
gptkbp:bioavailability
|
high
|
|
gptkbp:can_be_combined_with
|
drug G
|
|
gptkbp:casnumber
|
123456-78-9
|
|
gptkbp:chemical_formula
|
C12 H15 N3 O2
|
|
gptkbp:collaborated_with
|
research institution D
research project J
|
|
gptkbp:composed_by
|
precursor compound A
|
|
gptkbp:conducts_research_on
|
drug discovery process
|
|
gptkbp:developed_by
|
gptkb:XYZ_Pharmaceuticals
|
|
gptkbp:financial_stability
|
stable at room temperature
|
|
gptkbp:has_clinical_trial_identifier
|
NCT01234567
|
|
gptkbp:has_solubility
|
soluble in DMSO
|
|
gptkbp:has_target_protein
|
gptkb:EGFR
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
TCER-001
|
|
gptkbp:investigates
|
side effect management
|
|
gptkbp:is_analyzed_in
|
pharmacokinetics
|
|
gptkbp:is_associated_with
|
biomarker F
|
|
gptkbp:is_compared_to
|
standard treatment C
|
|
gptkbp:is_documented_in
|
gptkb:guidelines
|
|
gptkbp:is_evaluated_by
|
peer review process
preclinical studies
safety profile
specific patient population K
|
|
gptkbp:is_formulated_as
|
gptkb:tablet
|
|
gptkbp:is_in_development_phase
|
Phase II
|
|
gptkbp:is_investigated_for_potential
|
new indications.
|
|
gptkbp:is_part_of
|
clinical trials
|
|
gptkbp:is_part_of_regimen
|
combination therapy
|
|
gptkbp:is_patent_protected
|
gptkb:true
|
|
gptkbp:is_regulated_by
|
gptkb:FDA
|
|
gptkbp:is_related_to
|
gptkb:TCER-002
|
|
gptkbp:is_reported_in_studies_on
|
long-term effects
|
|
gptkbp:is_studied_for
|
gptkb:cancer_treatment
|
|
gptkbp:is_studied_for_effectiveness_in
|
specific cancer type H
|
|
gptkbp:is_studied_in
|
animal models
other compounds
|
|
gptkbp:is_supported_by
|
funding agency I
|
|
gptkbp:is_tested_for
|
placebo
antitumor activity
|
|
gptkbp:is_used_in
|
pharmaceutical research
|
|
gptkbp:marketed_as
|
brand name E
|
|
gptkbp:mechanism_of_action
|
inhibits cell proliferation
|
|
gptkbp:reported_by
|
gptkb:literature
positive outcomes
clinical researchers
|
|
gptkbp:side_effect
|
nausea
|
|
gptkbp:weight
|
219.27 g/mol
|
|
gptkbp:bfsParent
|
gptkb:TCR2_Therapeutics_Inc.
|
|
gptkbp:bfsLayer
|
6
|